Extensive-stage small cell lung cancer
Conditions
Interventions
Atezolizumab combined with chemotherapy group:None
Avelumab combined with chemotherapy group:None
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =18 years; 2. Histopathologically or cytologically confirmed SCLC; 3. Initially diagnosed at extensive stage; 4. The treatment regimen is first-line use of adebrelimab or atezolizumab combined with chemotherapy (the chemotherapy drugs are etoposide + platinum). 5. Complete relevant clinical data before treatment, with at least one measurable lesion; 6. ECOG performance status =2; 7.received adebrelimab or atezolizumab combined with chemotherapy for =2 cycles, with at least one efficacy assessment.
Exclusion criteria
Exclusion criteria: 1. Staged as localized at initial diagnosis; 2. Diagnosed with other primary malignant tumors within the past 5 years; 3. Complicated by hematological, immune, or other systemic diseases, or requiring long-term use of immunosuppressants or glucocorticoids; 4. Complicated by severe dysfunction of organs such as the heart, brain, kidneys, or liver; 5. ECOG score >2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression Free Survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR;Disease control rate, DCR; | — |
Countries
China
Contacts
Public ContactDongbo Jiang
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed